115279-73-7N#CC1(c2ccc(N)cc2)CCCC1GIBAIULVBOBDED-UHFFFAOYSA-N115279-73-7DTXSID40354291Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Uses1-(4-Aminophenyl)cyclopentanecarbonitrile-d8 is an intermediate used in the synthesis of Apatinib-d8 Hydrochloride (A726152), which is a labelled Apatinib (A726150). Apatinib is an orally available, small molecule multitargeted tyrosine kinase inhibitor. Apatinib selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Apatinib functions by inhibiting VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. Recent studies have shown that Apatinib enhances the efficacy of conventional chemotherapeutical drugs in side population (SP) cells and ABCB1-overexpressing leukemia cells.
No reaction records under the current filter.
Loading…